Paclitaxel Injection, Solution
Product Images NDC 16714-137

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Paclitaxel (NDC 16714-137). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

300mg-carton (Carton Label)

300mg-carton (Carton Label)
This is a description of a medication called Paclitaxel Injection, USP. It is a cytotoxic agent that requires dilution prior to intravenous infusion. The medication comes in a multiple dose vial of 50mL and contains 300mg/50mL (6mg/mL) of paclitaxel. The medication is manufactured for Northstar Rx LLC and by MSN Laboratories Private Limited in India. The packaging cautions that gloves should be worn when handling the containers and the medication should be protected from light. The usual dosage information is included in the insert, along with detailed directions for use and precautions. The NDC number for this medication is available.*
FDA Label Image

Fig-1 (Figure 1)

Fig-1 (Figure 1)
FDA Label Image

Fig-2 (Figure 2)

Fig-2 (Figure 2)
FDA Label Image

Fig-3 (Figure 3)

Fig-3 (Figure 3)
FDA Label Image

Fig-4 (Figure 4)

Fig-4 (Figure 4)
FDA Label Image

Fig-5 (Figure 5)

Fig-5 (Figure 5)
The text seems to be describing the "Proportion Disease Free" for the "Humber ot sk" in two different years, 2006 and 202%. However, this information is not complete as it lacks the context or more details. Therefore, it's difficult to determine what the values represent or how they were obtained.*
FDA Label Image

Fig-6 (Figure 6)

Fig-6 (Figure 6)
This text appears to be a graphical representation of disease-free proportions over a period of four years. The X-axis represents the four years, and the y-axis represents the proportion of individuals free of disease. Data is also presented in a table format, with Risk number and proportion of disease-free individuals indicated for each year.*
FDA Label Image

Fig-7 (Figure 7)

Fig-7 (Figure 7)
This appears to be information from a medical study or clinical trial. The text provides data on the proportion of individuals who are disease-free over a period of four years, as well as the number of events (likely cases of disease). The sample size is 96,963 and the hazard ratio (HR) is 0.83 with a 95% confidence interval between 0.67 and 1.01. The text also shows the number of individuals at risk over time.*
FDA Label Image

Fig-8 (Figure 8)

Fig-8 (Figure 8)
This is a medical report presenting data on a proportion of disease-free patients using AC+T treatment. It includes the number of events, Hazard Ratio (HR), confidence interval, and the number of patients at risk over 3 years. The text is not clear enough to provide context or additional information on the study or results.*
FDA Label Image

Structure (Structure)

Structure (Structure)
FDA Label Image

300mg-vial (Vial Label)

300mg-vial (Vial Label)
Paclitaxel Injection, USP is a cytotoxic agent used for intravenous infusion. Each mL of the solution contains 6 mg of paclitaxel, USP, along with semisynthetic polyoxyl 35 castor oil, nf, and dehydrated alcohol, USP. The usual dosage and dilution requirements can be found in the product insert. The solution comes in a 50 mL multiple dose vial and should be stored between 20°C to 25°C, protected from light. The product is manufactured by MSN Laboratories Private Limited in Telangana, India, and distributed by Northstar Rx LLC in Memphis, TN. Gloves should be worn at all times when handling containers. This text also includes the product's NDC and manufacturing date.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.